What's breaking now, across thousands of outlets.
Researchers combined a blood test to measure the biomarker p-tau217 and a genetic test that looks for a variant of the APOE gene.
We haven't written up this one. Newsweek has the full story — the link below goes straight to it.
The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.
A new program in B.C. trains advanced paramedics in how to treat heart attack patients with thrombolysis and clot-dissolving medication
Researchers at the University of California San Diego School of Medicine have published the first study to define early-onset cirrhosis caused by metabolic dysfunction-associated steatotic liver…
Bioactiv Matrix does not require specialised storage, allowing it to be used in areas such as disaster zones.
The National Health Insurance Authority has adopted Health Technology Assessment to guide healthcare spending and ensure resources are used efficiently in Read More…
